Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

WHO 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.

Van Deun A, Decroo T, Tahseen S, Trébucq A, Schwoebel V, Ortuno-Gutierrez N, de Jong BC, Rieder HL, Piubello A, Chiang CY.

Int J Antimicrob Agents. 2019 Oct 15. pii: S0924-8579(19)30277-8. doi: 10.1016/j.ijantimicag.2019.10.003. [Epub ahead of print]

PMID:
31626907
2.

Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB.

Van Deun A, Decroo T, Kuaban C, Noeske J, Piubello A, Aung KJM, Rieder HL.

Int J Tuberc Lung Dis. 2019 Sep 1;23(9):965-971. doi: 10.5588/ijtld.19.0053.

PMID:
31615602
3.

In reply: A human rights-based approach to tuberculosis diagnosis.

Van Deun A, Tahseen S, Affolabi D, Hossain MA, Joloba ML, Angra PK, Ridderhof JC, de Jong BC, Rieder HL.

Int J Tuberc Lung Dis. 2019 Aug 1;23(8):959-960. doi: 10.5588/ijtld.18.0133. No abstract available.

PMID:
31533887
4.

Multidrug-resistant tuberculosis.

Chiang CY, Van Deun A, Trébucq A, Piubello A, Schwoebel V, Rieder HL.

Lancet. 2019 Jul 27;394(10195):299. doi: 10.1016/S0140-6736(19)30046-7. No abstract available. Erratum in: Lancet. 2019 Aug 17;394(10198):564.

PMID:
31354138
5.

Outcome definitions for multidrug-resistant tuberculosis treated with shorter treatment regimens.

Schwoebel V, Chiang CY, Trébucq A, Piubello A, Aït-Khaled N, Koura KG, Heldal E, Van Deun A, Rieder HL.

Int J Tuberc Lung Dis. 2019 May 1;23(5):619-624. doi: 10.5588/ijtld.18.0798.

PMID:
31097072
6.

Reflections on the end TB strategy.

Rieder HL.

Indian J Tuberc. 2019 Jan;66(1):167-169. doi: 10.1016/j.ijtb.2019.02.003. Epub 2019 Feb 26. Review. No abstract available.

PMID:
30878063
7.

Sputum smear microscopy in the Xpert® MTB/RIF era.

Van Deun A, Tahseen S, Affolabi D, Hossain MA, Joloba ML, Angra PK, Ridderhof JC, de Jong BC, Rieder HL.

Int J Tuberc Lung Dis. 2019 Jan 1;23(1):12-18. doi: 10.5588/ijtld.18.0553. Epub 2018 Dec 19.

PMID:
30567624
8.

Impact of quality improvement in tuberculosis laboratories in low- and lower-middle-income countries: a systematic review.

Olaru ID, Albert H, Zallet J, Werner UE, Ahmed N, Rieder HL, Salfinger M, Kranzer K.

Int J Tuberc Lung Dis. 2018 Mar 1;22(3):309-320. doi: 10.5588/ijtld.17.0629.

9.

Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs.

Van Deun A, Decroo T, Piubello A, de Jong BC, Lynen L, Rieder HL.

Int J Tuberc Lung Dis. 2018 Mar 1;22(3):239-245. doi: 10.5588/ijtld.17.0660. Review.

PMID:
29471899
10.

Should gatifloxacin be included in the model list of essential medicines?

Chiang CY, Trébucq A, Piubello A, Rieder HL, Van Deun A.

Eur Respir J. 2018 Feb 7;51(2). pii: 1702329. doi: 10.1183/13993003.02329-2017. Print 2018 Feb. No abstract available.

11.

Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries.

Trébucq A, Schwoebel V, Kashongwe Z, Bakayoko A, Kuaban C, Noeske J, Hassane S, Souleymane B, Piubello A, Ciza F, Fikouma V, Gasana M, Ouedraogo M, Gninafon M, Van Deun A, Cirillo DM, Koura KG, Rieder HL.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):17-25. doi: 10.5588/ijtld.17.0498. Epub 2017 Nov 17.

PMID:
29149917
12.

Informative, large cohorts of meningeal tuberculosis.

Rieder HL.

Indian J Tuberc. 2017 Oct;64(4):241-242. doi: 10.1016/j.ijtb.2017.07.001. Epub 2017 Jul 15. No abstract available.

PMID:
28941845
13.

Gastric aspiration: routine use for diagnosis of pulmonary tuberculosis patients unable to expectorate sputum.

Kim SJ, Rieder HL.

Public Health Action. 2017 Jun 21;7(2):82. doi: 10.5588/pha.17.0042. No abstract available.

14.

Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.

Heldal E, Van Deun A, Chiang CY, Rieder HL.

Eur Respir J. 2017 Jun 1;49(6). pii: 1700228. doi: 10.1183/13993003.00228-2017. Print 2017 Jun. No abstract available.

15.

Behind the great walls.

Schoch OD, Rieder HL.

Int J Tuberc Lung Dis. 2017 Jun 1;21(6):601. doi: 10.5588/ijtld.17.0175. No abstract available.

PMID:
28482952
16.

Rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis.

Rieder HL, Van Deun A.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):123-124. doi: 10.5588/ijtld.16.0619. No abstract available.

PMID:
28157478
17.

Influenza Pandemics and Tuberculosis Mortality in 1889 and 1918: Analysis of Historical Data from Switzerland.

Zürcher K, Zwahlen M, Ballif M, Rieder HL, Egger M, Fenner L.

PLoS One. 2016 Oct 5;11(10):e0162575. doi: 10.1371/journal.pone.0162575. eCollection 2016.

18.

Gatifloxacin for short, effective treatment of multidrug-resistant tuberculosis.

Chiang CY, Van Deun A, Rieder HL.

Int J Tuberc Lung Dis. 2016 Sep;20(9):1143-7. doi: 10.5588/ijtld.15.0884.

PMID:
27510237
19.

Challenges in the diagnosis of extrapulmonary tuberculosis.

Rieder HL.

Indian J Tuberc. 2016 Apr;63(2):67-8. doi: 10.1016/j.ijtb.2016.05.013. Epub 2016 Jun 16. No abstract available.

PMID:
27451811
20.

Standard Genotyping Overestimates Transmission of Mycobacterium tuberculosis among Immigrants in a Low-Incidence Country.

Stucki D, Ballif M, Egger M, Furrer H, Altpeter E, Battegay M, Droz S, Bruderer T, Coscolla M, Borrell S, Zürcher K, Janssens JP, Calmy A, Mazza Stalder J, Jaton K, Rieder HL, Pfyffer GE, Siegrist HH, Hoffmann M, Fehr J, Dolina M, Frei R, Schrenzel J, Böttger EC, Gagneux S, Fenner L.

J Clin Microbiol. 2016 Jul;54(7):1862-1870. doi: 10.1128/JCM.00126-16. Epub 2016 May 18.

21.

The King's Evil and the Royal Touch: the medical history of scrofula.

Murray JF, Rieder HL, Finley-Croswhite A.

Int J Tuberc Lung Dis. 2016 Jun;20(6):713-6. doi: 10.5588/ijtld.16.0229. No abstract available.

PMID:
27155172
22.

Tuberculosis Mortality and Living Conditions in Bern, Switzerland, 1856-1950.

Zürcher K, Ballif M, Zwahlen M, Rieder HL, Egger M, Fenner L.

PLoS One. 2016 Feb 16;11(2):e0149195. doi: 10.1371/journal.pone.0149195. eCollection 2016.

23.

Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.

Rigouts L, Coeck N, Gumusboga M, de Rijk WB, Aung KJ, Hossain MA, Fissette K, Rieder HL, Meehan CJ, de Jong BC, Van Deun A.

J Antimicrob Chemother. 2016 Feb;71(2):314-23. doi: 10.1093/jac/dkv360. Epub 2015 Nov 24.

24.

Do Instructional Videos on Sputum Submission Result in Increased Tuberculosis Case Detection? A Randomized Controlled Trial.

Mhalu G, Hella J, Doulla B, Mhimbira F, Mtutu H, Hiza H, Sasamalo M, Rutaihwa L, Rieder HL, Seimon T, Mutayoba B, Weiss MG, Fenner L.

PLoS One. 2015 Sep 29;10(9):e0138413. doi: 10.1371/journal.pone.0138413. eCollection 2015.

25.

High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.

Kuaban C, Noeske J, Rieder HL, Aït-Khaled N, Abena Foe JL, Trébucq A.

Int J Tuberc Lung Dis. 2015 May;19(5):517-24. doi: 10.5588/ijtld.14.0535.

PMID:
25868018
26.

Jean-Antoine Villemin: ending an Alpine divide.

Rieder HL.

Int J Tuberc Lung Dis. 2015 Mar;19(3):253. doi: 10.5588/ijtld.15.0012. No abstract available.

PMID:
25686126
27.

Tracking a tuberculosis outbreak over 21 years: strain-specific single-nucleotide polymorphism typing combined with targeted whole-genome sequencing.

Stucki D, Ballif M, Bodmer T, Coscolla M, Maurer AM, Droz S, Butz C, Borrell S, Längle C, Feldmann J, Furrer H, Mordasini C, Helbling P, Rieder HL, Egger M, Gagneux S, Fenner L.

J Infect Dis. 2015 Apr 15;211(8):1306-16. doi: 10.1093/infdis/jiu601. Epub 2014 Oct 30.

28.

Of drug susceptibility test results, gold standards, and test operating characteristics.

Rieder HL.

Indian J Tuberc. 2014 Jul;61(3):181-2. No abstract available.

PMID:
25241563
29.

Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.

Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, Rieder HL.

Int J Tuberc Lung Dis. 2014 Oct;18(10):1180-7. doi: 10.5588/ijtld.14.0100.

PMID:
25216831
30.

Molecular epidemiology of tuberculosis in Cambodian children.

Schopfer K, Rieder HL, Steinlin-Schopfer JF, van Soolingen D, Bodmer T, Chantana Y, Studer P, Laurent D, Zwahlen M, Richner B.

Epidemiol Infect. 2015 Apr;143(5):910-21. doi: 10.1017/S0950268814001769. Epub 2014 Jul 22.

PMID:
25050615
31.

Ninety years after The Magic Mountain: world literature inspired by a misdiagnosis, a tribute to Christian Virchow.

Rieder HL.

Int J Tuberc Lung Dis. 2014 Jul;18(7):761-2. doi: 10.5588/ijtld.13.0183. No abstract available.

PMID:
24902548
32.

The dynamics of tuberculosis epidemiology.

Rieder HL.

Indian J Tuberc. 2014 Jan;61(1):19-29. Review.

PMID:
24640341
33.

Serial screening for latent tuberculosis infection in healthcare workers in low-risk settings.

Zellweger JP, Rieder HL.

Am J Respir Crit Care Med. 2014 Jan 1;189(1):3-4. doi: 10.1164/rccm.201311-2062ED. No abstract available.

PMID:
24381985
34.

The sensitivity of an interferon-γ release assay in microbiologically confirmed pediatric tuberculosis.

Schopfer K, Rieder HL, Bodmer T, Steinlin-Schopfer JF, Chantana Y, Studer P, Laurent D, Richner B.

Eur J Pediatr. 2014 Mar;173(3):331-6. doi: 10.1007/s00431-013-2161-x. Epub 2013 Sep 25.

PMID:
24065457
35.

Efficient, quality-assured data capture in operational research through innovative use of open-access technology.

Kumar AM, Naik B, Guddemane DK, Bhat P, Wilson N, Sreenivas AN, Lauritsen JM, Rieder HL.

Public Health Action. 2013 Mar 21;3(1):60-2. doi: 10.5588/pha.13.0004.

36.

HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosis.

Fenner L, Egger M, Bodmer T, Furrer H, Ballif M, Battegay M, Helbling P, Fehr J, Gsponer T, Rieder HL, Zwahlen M, Hoffmann M, Bernasconi E, Cavassini M, Calmy A, Dolina M, Frei R, Janssens JP, Borrell S, Stucki D, Schrenzel J, Böttger EC, Gagneux S; Swiss HIV Cohort and Molecular Epidemiology of Tuberculosis Study Groups.

PLoS Genet. 2013;9(3):e1003318. doi: 10.1371/journal.pgen.1003318. Epub 2013 Mar 7.

37.

The enigma of extra-pulmonary tuberculosis.

Rieder HL.

Int J Tuberc Lung Dis. 2013 Feb;17(2):144. doi: 10.5588/ijtld.12.0972. No abstract available.

PMID:
23317947
38.

Changes in body weight and tuberculosis treatment outcome in Viet Nam.

Hoa NB, Lauritsen JM, Rieder HL.

Int J Tuberc Lung Dis. 2013 Jan;17(1):61-6. doi: 10.5588/ijtld.12.0369. Epub 2012 Nov 9.

PMID:
23146565
39.

Of tangible benefits that remain unexplained: the Papworth village movement to take care of tuberculous families.

Rieder HL.

Am J Respir Crit Care Med. 2012 Sep 1;186(5):397-8. doi: 10.1164/rccm.201207-1183ED. No abstract available.

PMID:
22942343
40.

In reply to 'Should Xpert® MTB/RIF be rolled out in low-income countries?' [Correspondence].

Trébucq A, Harries AD, Rieder HL.

Int J Tuberc Lung Dis. 2012 May 1;16(5):703-704. doi: 10.5588/ijtld.12.0034-2. No abstract available.

PMID:
29070251
41.

The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement.

Bumbacea D, Arend SM, Eyuboglu F, Fishman JA, Goletti D, Ison MG, Jones CE, Kampmann B, Kotton CN, Lange C, Ljungman P, Milburn H, Morris MI, Muller E, Muñoz P, Nellore A, Rieder HL, Sester U, Theodoropoulos N, Wagner D, Sester M.

Eur Respir J. 2012 Oct;40(4):990-1013. Epub 2012 Apr 10. Review.

42.

Time to unsuccessful tuberculosis treatment outcome, Cambodia, China, and Viet Nam.

Hoa NB, Sokun C, Wei C, Lauritsen JM, Rieder HL.

Public Health Action. 2012 Mar 21;2(1):15-20. doi: 10.5588/pha.11.0024.

43.

Adequacy of anti-tuberculosis drug prescriptions in Viet Nam.

Hoa NB, Lauritsen JM, Rieder HL.

Public Health Action. 2012 Mar 21;2(1):5-9. doi: 10.5588/pha.11.0015.

44.

DOT, S, or DOTS?

Van Deun A, Rieder HL.

Public Health Action. 2012 Mar 21;2(1):3-4. doi: 10.5588/pha.12.0007. No abstract available.

45.

Laboratory diagnosis of tuberculosis in a large pediatric hospital in Cambodia.

Schopfer K, Rieder HL, Bodmer T, Steinlin-Schopfer JF, Chantana Y, Somathea T, Studer P, Laurent D, Richner B.

Int J Tuberc Lung Dis. 2012 Apr;16(4):503-9. doi: 10.5588/ijtld.11.0592.

PMID:
22326031
46.

Human resource requirements for quality-assured electronic data capture of the tuberculosis case register.

Hoa NB, Sokun C, Wei C, Lauritsen JM, Rieder HL.

BMC Res Notes. 2012 Jan 27;5:75. doi: 10.1186/1756-0500-5-75.

47.

Isoniazid preventive therapy for all: are we ready?

Fenner L, Rieder HL.

Int J Tuberc Lung Dis. 2011 Oct;15(10):1281-2. doi: 10.5588/ijtld.11.0011. No abstract available.

PMID:
22283884
48.

Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infection.

Fenner L, Gagneux S, Helbling P, Battegay M, Rieder HL, Pfyffer GE, Zwahlen M, Furrer H, Siegrist HH, Fehr J, Dolina M, Calmy A, Stucki D, Jaton K, Janssens JP, Stalder JM, Bodmer T, Ninet B, Böttger EC, Egger M; Swiss HIV Cohort Study Group; Molecular Epidemiology of Tuberculosis Study Group.

J Clin Microbiol. 2012 Feb;50(2):388-95. doi: 10.1128/JCM.05392-11. Epub 2011 Nov 23.

49.

Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?

Trébucq A, Enarson DA, Chiang CY, Van Deun A, Harries AD, Boillot F, Detjen A, Fujiwara PI, Graham SM, Monedero I, Rusen ID, Rieder HL.

Int J Tuberc Lung Dis. 2011 Dec;15(12):1567-72. doi: 10.5588/ijtld.11.0392. Epub 2011 Oct 13.

PMID:
22005110
50.

Duration of isoniazid preventive therapy in HIV-infected patients.

Rieder HL.

Lancet. 2011 Oct 1;378(9798):1215-6; author reply 1216-7. doi: 10.1016/S0140-6736(11)61531-6. No abstract available.

PMID:
21962551

Supplemental Content

Loading ...
Support Center